secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-005486
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet Bio reports prula-cel Phase 1 enrollment doubles to 20+ patients; FDA allows outpatient dosing for SLE/LN
--------------------------------------------------------------------------------

- Enrollment in prula-cel autoimmune Phase 1 program doubled to over 20 patients as of Dec 31, 2025.
- FDA alignment achieved to allow outpatient dosing of SLE and lupus nephritis patients in ongoing and future trials.
- Plans to request FDA meeting in Q2 2026 to discuss potential Phase 2 pivotal trial design for prula-cel.
- Regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer expected in H1 2026.
- Cash runway extended into H2 2027 following $74.8M net proceeds from October 2025 equity offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000119312526005486/0001193125-26-005486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000119312526005486/acet-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-005486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer